Skip to main content
. 2024 Jan 30;32:1–10. doi: 10.1016/j.jmsacl.2024.01.006

Fig. 1.

Fig. 1

Basis for a therapeutic role for carnitine in propionic acidemia. Due to a metabolic block, propionyl-coenzyme A accumulates in the mitochondrial matrix. An alternative pathway exists to remove this toxic intermediate as propionyl-carnitine, a harmless by-product, but there is insufficient endogenous carnitine available. Supplemental L-carnitine enhances this pathway, thereby releasing coenzyme-A for its vital functions.